Weight-loss drug semaglutide alters reward-seeking behavior in healthy mice

A recent scientific study involving healthy mice has demonstrated that the weight-loss drug semaglutide impacts reward-seeking behavior and brain activity. Published in the journal Molecular Brain, the research conducted by scientists from Aarhus University reveals the drug's effect on the nucleus accumbens, a brain region crucial for processing motivation, pleasure, and reward.

Semaglutide, commonly prescribed for diabetes and obesity, works by mimicking the naturally occurring hormone GLP-1, which regulates appetite and blood sugar levels. The researchers divided adult male mice into two groups, one receiving weekly injections of semaglutide and the other receiving daily injections. After eight weeks, the daily-dosed mice displayed significant weight loss and alterations in behavior, such as increased anxiety and reduced exploration.

These behavioral changes were notably absent in the weekly-dosed group. The drug's impact on neural activity was also assessed by recording brain waves in the nucleus accumbens, which showed a shift in wave patterns, indicating a dampened reward anticipation system. However, the study's limitations include its small sample size and the use of anesthesia during brain wave recording, which may not accurately reflect the drug's effects on awake, behaving animals.